Scientists conducted an in-depth analysis of a clinical cohort of HCC using high-coverage phosphoproteomic. Therapeutic targets were validated using liver cancer cell lines and HCC patient-derived xenograft mouse models that corresponded to the phosphoproteomic subtypes of HCC.
[Hepatology]